Severe Congenital Neutropenia 6 (SCN6)

Severe Congenital Neutropenia 6 (SCN6) is a rare, inherited immune disorder present from birth. The white blood cells called neutrophils—which fight bacteria and fungi—are very low in number most of the time. Because neutrophils are missing, babies and young children get serious, repeated infections of the skin, mouth, lungs, gut, and blood. SCN6 happens when a child inherits disease-causing changes (variants) in both copies of a gene called JAGN1. This gene helps new white blood cells form and move through the cell’s secretory pathway; when it does not work, neutrophils don’t mature well and don’t survive, so the body cannot keep enough of them in the blood. Many children need long-term treatment with G-CSF (a growth factor) and careful infection prevention. Some patients respond poorly to G-CSF, and a bone marrow transplant may be considered. Without good care, there is risk of life-threatening infections; with modern care, many patients do much better. Orpha+3PMC+3Frontiers+3

Severe congenital neutropenia 6 is a rare, inherited immune disorder in which the bone marrow cannot make enough mature neutrophils, the white blood cells that first fight germs. SCN6 is caused by harmful changes in the JAGN1 gene. Children are usually sick early in life with repeated bacterial and fungal infections, mouth ulcers, gum disease, skin infections, and sometimes bone changes such as low bone density. Many patients respond poorly to standard G-CSF compared with other SCN types, and some need stem-cell transplant. Because lifelong severe neutropenia also raises the risk of bone-marrow problems like MDS/AML, expert follow-up is essential. ASH Publications+3MedlinePlus+3PMC+3

Other names

• Autosomal recessive severe congenital neutropenia due to JAGN1 deficiency

• JAGN1-associated severe congenital neutropenia

• SCN6 (the cataloged subtype number for JAGN1-related SCN)

• Sometimes included within the broader umbrella of Kostmann-type congenital neutropenia (autosomal-recessive SCN). NCBI+2malacards.org+2

Types

Doctors often speak about SCN (severe congenital neutropenia) by gene and by clinical pattern rather than “types” within SCN6. For JAGN1-related SCN specifically, you may see:

1. Classic SCN6 with G-CSF responsiveness – very low neutrophil counts from infancy with frequent infections, some increase in neutrophil counts on G-CSF. Frontiers

2. SCN6 with poor/low response to G-CSF – same core picture, but minimal rise in neutrophils despite high-dose G-CSF; this group sometimes needs transplant earlier. Frontiers

3. SCN6 with extra features (“syndromic” clues) – some patients have facial differences, growth issues, bleeding tendency, or other organ findings alongside neutropenia. These are variable and not always present. turkjpediatr.org+1

Causes

Note: SCN6 itself has one root cause—harmful variants in both copies of JAGN1. Below are 20 ways this cause shows up biologically or clinically, and risk contexts that make SCN6 more likely to be found. Each item describes what goes wrong and why that leads to neutropenia or infections.

1. Biallelic JAGN1 variants (autosomal recessive inheritance). A child inherits one faulty JAGN1 gene from each parent; both are needed for normal neutrophil development. NCBI+1

2. Defective secretory pathway in myeloid precursors. JAGN1 helps early neutrophil cells handle proteins in the endoplasmic reticulum/secretory system; failure triggers cell stress and death. PMC

3. Impaired neutrophil maturation (“maturation arrest”). Cells stall at the promyelocyte/myelocyte stage, so mature neutrophils do not appear in blood. Medscape

4. Increased apoptosis (cell death) of precursors. ER stress and mis-folded protein responses shorten the life of developing neutrophils. PMC

5. Aberrant glycosylation/trafficking of key proteins. Faulty processing reduces function of proteins neutrophils need to survive, move, and kill microbes. PMC

6. Reduced antimicrobial granule content or release. When granules don’t form or release properly, neutrophils (if present) kill germs poorly. PMC

7. Diminished response to G-CSF signaling in some patients. Even with therapy, neutrophils may not rise much; mechanism appears linked to the secretory/ER stress defect. Frontiers

8. Early-onset susceptibility to bacterial infections. With very low ANC, common bacteria become dangerous, causing skin, lung, ear, and blood infections. Orpha

9. Higher risk of severe fungal infections. Neutrophils are crucial for antifungal defense; very low counts increase risk of invasive candidiasis or aspergillosis. MedlinePlus

10. Mucosal barrier breakdown. Mouth sores and gingivitis allow bacteria to enter the bloodstream more easily. Medscape

11. Recurrent pneumonias. Low neutrophil numbers and weak microbe-killing raise lung infection frequency and severity. Orpha

12. Cell-intrinsic myeloid dysfunction beyond low numbers. Even existing neutrophils may function abnormally (chemotaxis, killing); this adds to infection risk. PMC

13. Variable bleeding tendency (rare). Some reports describe bleeding with JAGN1 deficiency, possibly from broader secretory or platelet granule effects. Frontiers

14. Growth or developmental concerns in some children. Chronic infections and systemic stress can impair growth and energy. BioMed Central

15. Consanguinity (family relatedness). Increases chance of inheriting the same rare JAGN1 variant from both parents. PMC

16. Family history of early severe infections or infant deaths. Suggests a recessive immune disorder in the family. Medscape

17. Misclassification as “idiopathic neutropenia.” Without genetic testing, SCN6 may be missed and labeled unexplained. Gene panels help reveal the cause. Mayo Clinic Laboratories

18. Bone marrow failure phenotype. The marrow cannot produce adequate mature neutrophils, part of a broader marrow weakness picture. NCBI

19. Risk of serious sepsis. Profound, persistent neutropenia lets minor infections become systemic quickly. Orpha

20. Potential evolution/complications with long disease duration. As in other SCN forms, ongoing marrow stress and treatment exposures necessitate monitoring for complications. (Data continue to evolve.) Medscape

Symptoms and everyday signs

1. Fever that keeps coming back. The body signals infection because it cannot raise enough neutrophils to fight germs. Seek care for any fever in infants with SCN. Orpha

2. Skin infections and abscesses. Cuts, hair follicles, or diaper area can swell, redden, and fill with pus (sometimes little pus because neutrophils are few). Orpha

3. Mouth ulcers and sore gums. Painful sores, gingivitis, and gum bleeding are common because germs invade when neutrophil defense is weak. Medscape

4. Ear infections (otitis media). Recurrent ear pain or discharge due to bacteria thriving in the middle ear. Orpha

5. Sinus infections. Blocked, painful sinuses that do not clear easily. Orpha

6. Pneumonia. Cough, fast breathing, chest pain; can become severe quickly without neutrophils. Orpha

7. Bloodstream infection (sepsis). Fevers, chills, lethargy; a medical emergency in SCN. Orpha

8. Belly pain and diarrhea. Gut infections or inflammation due to weak mucosal defense. Orpha

9. Bone pain or tenderness. Sometimes from infections or marrow stress. Medscape

10. Slow weight gain or growth issues. Frequent illness and inflammation can reduce appetite and growth. BioMed Central

11. Fungal infections (thrush, skin). Yeast infections are more frequent when neutrophils are very low. MedlinePlus

12. Wound infections that heal slowly. Cuts or surgical sites may stay red and sore longer than normal. Orpha

13. Nasal crusting or sores. Chronic nose infections can cause irritation and bleeding. Orpha

14. Bleeding tendency (rarely reported). Some JAGN1 cases describe easy bruising or bleeding; not universal. Frontiers

15. Fatigue and irritability. Recurrent infection and inflammation make children tired and uncomfortable. Orpha

Diagnostic tests

A) Physical examination (what the clinician looks for)

1. General exam during fever. Checks temperature, energy level, hydration, and signs of sepsis; in SCN any fever needs urgent assessment. Orpha

2. Skin and soft-tissue check. Looks for boils, redness, warmth, pus, or tenderness that suggest bacterial infection. Orpha

3. Mouth and gum inspection. Finds ulcers, gingivitis, or thrush that point to neutropenia-related mucosal problems. Medscape

4. Lung exam. Listens for crackles or wheeze that could indicate pneumonia needing quick treatment. Orpha

5. Growth and nutrition review. Tracks weight/height and feeding issues which may reflect frequent infections or chronic inflammation. BioMed Central

B) Manual/bedside assessments (simple calculations or charts)

6. Absolute Neutrophil Count (ANC) calculation. From CBC: ANC = WBC × (% neutrophils + bands). In SCN6, ANC is usually <500/µL persistently. Medscape

7. Fever charting and infection diary. Families and clinicians record fevers/infections to gauge severity and treatment response over time. Medscape

8. Medication response tracking (G-CSF log). Daily ANC/clinical notes to see whether G-CSF raises counts—important because some JAGN1 cases respond poorly. Frontiers

C) Laboratory & pathological tests (core of the workup)

9. Complete Blood Count (CBC) with differential. Shows very low neutrophils with otherwise variable results; repeated tests confirm persistence. Medscape

10. Blood cultures during fever. Finds bacteria in the blood and guides antibiotic choice. Medscape

11. C-reactive protein/procalcitonin. Inflammation markers that help assess severity of infection. Medscape

12. Bone marrow aspirate/biopsy. Typically shows maturation arrest of myeloid cells (few mature neutrophils), supporting congenital neutropenia. Medscape

13. Genetic testing (JAGN1 sequencing). Confirms the diagnosis of SCN6 by finding pathogenic variants in both JAGN1 copies. Panels cover many SCN genes. Mayo Clinic Laboratories+1

14. Flow cytometry for neutrophil function (e.g., DHR). Rules out other disorders like chronic granulomatous disease and may assess oxidative burst. Medscape

15. Immunoglobulin levels and basic immune screen. Looks for broader immune problems sometimes seen with recurrent infections. Orpha

16. Fungal biomarkers or cultures when indicated. For persistent fevers or lung findings, tests for invasive fungal disease. MedlinePlus

D) Electrodiagnostic & supportive instrument tests

Electrodiagnostic tests are not core to diagnosing SCN6, but clinicians may use supportive studies when infections are serious.

17. Electrocardiogram (ECG) during sepsis or high-dose medicines to monitor heart rhythm and perfusion status. (Supportive care in severe infection.) Medscape

18. Pulse oximetry/continuous monitors in pneumonia or sepsis to track oxygen and vital signs. (Bedside monitoring rather than a diagnostic of SCN itself.) Medscape

E) Imaging tests (look for infection sites and complications)

19. Chest X-ray. Detects pneumonia, abscess, or other lung problems that drive fever. Medscape

20. Ultrasound or CT/MRI of infected areas. Finds deep abscesses (liver, spleen, soft tissue) when fever persists or pain localizes. Medscape

Non-pharmacological treatments (therapies & other measures)

1) Hand-hygiene coaching at home
Regular, correct handwashing (or sanitizer when soap/water aren’t available) lowers the number of germs that reach the mouth, nose, and eyes. Families learn “when” (before food, after bathroom, after public places, after touching pets) and “how” (20 seconds, all surfaces). In SCN6, fewer neutrophils mean every exposure matters; cutting exposures reduces infections. Purpose: reduce germ transfer. Mechanism: mechanical removal and alcohol-mediated kill of microbes on skin. CDC+1

2) Food safety program (not a strict “neutropenic diet”)
Modern guidelines no longer support rigid “neutropenic diets,” but they strongly endorse food safety: cook meats/eggs thoroughly, rinse produce well, avoid cross-contamination (separate boards for meat vs produce), and refrigerate promptly. This approach protects SCN6 patients without unnecessary restrictions. Purpose: prevent food-borne infection. Mechanism: heat kills pathogens; washing and separation reduce inoculum. PMC+1

3) Oral care routine (soft brush + saline/CHX as advised)
Daily toothbrushing with a soft brush plus saline rinses, and short courses of chlorhexidine (when clinicians recommend it), lower mouth sores and bacterial load—key because oral ulcers often seed bloodstream infections when neutrophils are low. Purpose: prevent mucositis and gingivitis. Mechanism: mechanical plaque removal; CHX reduces oral microbial burden. SpringerLink+1

4) Skin care & bathing
Daily showers and moisturizers keep skin from cracking, which blocks common entry points for bacteria. Quick attention to cuts (soap, water, topical antiseptic) and avoiding shared razors help. Purpose: maintain skin barrier. Mechanism: cleanses microbes and preserves the lipid barrier. CDC

5) Fever action plan
Families get written instructions: if temperature ≥38.0°C (100.4°F), call or go to emergency care immediately. Early antibiotics save lives in profound neutropenia. Purpose: shorten time to treatment. Mechanism: rapid triage and empiric antimicrobials before sepsis progresses. CDC

6) Safe pet and household practices
Use gloves for litter boxes and pet clean-ups; wash hands afterward; keep pets vaccinated and dewormed; avoid contact with animal waste and reptiles. Purpose: reduce zoonotic exposure. Mechanism: limits high-load exposures from animal flora. CDC

7) Vaccination optimization (household & patient)
SCN6 affects neutrophils, not antibody production. Patients usually follow routine inactivated vaccines; household influenza shots reduce exposure at home. Specialist advice guides any live-vaccine decisions. Purpose: reduce vaccine-preventable infections. Mechanism: active immunity in patient and “cocooning” via household vaccination. CDC

8) Crowd and sick-contact avoidance
During local outbreaks or when ANC is very low, avoiding crowded indoor spaces and sick contacts decreases exposure dose. Purpose: minimize exposure events. Mechanism: lowers encounter rate with infectious droplets. CDC

9) Neutropenia-aware school plan
Coordination with school: send home sick classmates, allow hand sanitizer, flexible attendance after fevers or infections. Purpose: safe participation in school. Mechanism: reduces contact during peak infectious periods. CDC

10) Environmental cleaning at home
Routine disinfection of high-touch surfaces (handles, phones, remotes) and proper laundry of soiled items reduces pathogen load. Purpose: cut fomite transmission. Mechanism: detergent and disinfectants destroy microbes on surfaces. CDC

11) Gardening & soil precautions
Wear gloves when gardening; avoid compost handling; wash hands after outdoor play. Purpose: reduce fungal/bacterial soil exposures. Mechanism: barrier protection and immediate decontamination. CDC

12) Perineal care & constipation prevention
Use stool-softeners and hydration to avoid anal fissures; avoid rectal thermometers/suppositories. Purpose: prevent perianal entry points and bacteremia. Mechanism: maintains mucosal integrity and avoids trauma. Healthline

13) Early dental evaluation
Regular dental checks remove plaque niches and treat gum disease promptly—important sources for bacteremia in neutropenia. Purpose: prevent odontogenic seeding. Mechanism: professional debridement reduces pathogen reservoirs. SpringerLink

14) Nasal/sinus care
Saline sprays or rinses may ease sinus drainage; see ENT for recurrent sinusitis to consider culture-guided care. Purpose: reduce sinus infection burden. Mechanism: mechanical clearance of secretions reduces microbial load. Infectious Diseases Society of America

15) Travel precautions
Pre-travel consults, destination-specific vaccines (inactivated where appropriate), travel antibiotics as instructed, and strict food/water safety. Purpose: prevent travel-related infections. Mechanism: pre-exposure protection and rapid treatment availability. CDC

16) Household education sessions
Teach family to recognize early infection signs (fever, chills, new cough, mouth ulcers, skin redness) and to act fast. Purpose: earlier presentation. Mechanism: improves detection and reduces delays to antibiotics. CDC

17) School/daycare infection control
Promote coughing etiquette, handwashing stations, and routine surface cleaning. Purpose: community risk reduction. Mechanism: fewer droplets and fomites. CDC

18) Nutrition pattern focused on safety
Well-balanced diet with safe prep (thorough cooking, produce washing). Avoid raw eggs, undercooked meats, and unpasteurized dairy. Purpose: maintain growth while minimizing foodborne risk. Mechanism: eliminates high-risk foods and cross-contamination. Memorial Sloan Kettering Cancer Center

19) Oral cryotherapy during stomatitis-provoking care (selected cases)
For mucositis risk (e.g., during certain therapies), “ice-chip” oral cooling can help. Purpose: reduce mucosal injury and ulcer load. Mechanism: vasoconstriction limits cytotoxic exposure to mucosa. PMC

20) Structured emergency pathway with your hospital
Pre-registered triage instructions, “neutropenia alert” cards, and antibiotic protocols shorten door-to-needle times. Purpose: safer emergency care. Mechanism: protocol-driven rapid antibiotics. Infectious Diseases Society of America

---

Drug treatments

Important context: In SCN6 (JAGN1), G-CSF is the cornerstone, but some patients respond poorly and need HSCT. Below are the most relevant medicines; when FDA labeling supports severe chronic neutropenia (SCN), I cite the exact label. Other items (e.g., infection prophylaxis) follow specialty guidelines; they are commonly used but not specifically FDA-approved “for SCN.” Always treat under specialist care. PMC+1

1) Filgrastim (NEUPOGEN®)
Class: G-CSF. Dose/Timing: For congenital neutropenia: starting 6 mcg/kg twice daily SC, then titrate by ANC and clinical response; long-term maintenance varies. Purpose: raise neutrophil counts and cut infections/ulcers. Mechanism: stimulates neutrophil production and release from marrow. Side effects: bone pain, splenomegaly, rare splenic rupture; monitor counts and spleen. Evidence: FDA label explicitly includes severe chronic neutropenia (congenital, cyclic, idiopathic) as an indication; long-term registry data confirm effectiveness with individualized dosing. FDA Access Data+2FDA Access Data+2

2) Filgrastim-sndz (ZARXIO®)
Class: G-CSF biosimilar. Dose/Timing: Congenital neutropenia: 6 mcg/kg SC twice daily initially; adjust to keep ANC in safe range. Purpose/Mechanism: as above. Side effects: bone pain, leukocytosis, splenic issues (rare). Evidence: FDA PI specifies dosing for congenital neutropenia and outlines monitoring. FDA Access Data

3) Filgrastim-aafi (NIVESTYM®)
Class: G-CSF biosimilar. Dose/Timing: 6 mcg/kg SC twice daily for congenital neutropenia; titrate to response. Purpose/Mechanism: same as filgrastim originator. Side effects: similar to class. Evidence: FDA label includes severe chronic neutropenia and provides dosing/monitoring guidance. FDA Access Data+1

4) Filgrastim-ayow (RELEUKO®)
Class: G-CSF biosimilar. Dose/Timing: FDA-labeled for severe chronic neutropenia with the same starting approach (6 mcg/kg twice daily). Purpose/Mechanism: boosts neutrophil production and release. Side effects: bone pain, rare splenic issues; monitor ANC. Evidence: 2025 FDA label includes SCN indication. FDA Access Data

5) Broad-spectrum IV antibiotics for febrile neutropenia (e.g., cefepime, piperacillin-tazobactam) — guided by local protocols
Class: Antibacterial. Dose/Timing: Start immediately with fever ≥38.0°C; weight-based dosing per pediatric/ID protocols. Purpose: treat life-threatening infections during profound neutropenia. Mechanism: rapidly kills likely pathogens while cultures are pending. Side effects: drug-specific (e.g., rash, diarrhea). Evidence: IDSA/ASCO fever-and-neutropenia guidance endorses urgent empiric therapy for high-risk neutropenia. Infectious Diseases Society of America

6) Antibacterial prophylaxis in defined high-risk periods (e.g., fluoroquinolone in adolescents/adults meeting high-risk criteria)
Class: Antibacterial. Dose/Timing: During expected profound, protracted neutropenia per ID specialist. Purpose: reduce invasive bacterial infections when risk is extreme. Mechanism: suppresses colonizing Gram-negatives. Side effects: resistance, tendinopathy (fluoroquinolones), C. difficile. Evidence: IDSA/ASCO prophylaxis guideline (adult oncology; extrapolated with caution to congenital states) recommends prophylaxis for profound, prolonged neutropenia. Infectious Diseases Society of America

7) Antifungal prophylaxis during prolonged severe neutropenia (selected cases)
Class: Antifungals (e.g., triazoles). Dose/Timing: Specialist-guided during high-risk windows. Purpose: prevent invasive fungal disease. Mechanism: inhibits fungal cell membrane synthesis. Side effects: hepatotoxicity, drug interactions. Evidence: Included as recommended for certain high-risk neutropenic populations. Infectious Diseases Society of America

8) Antiviral prophylaxis when indicated (e.g., acyclovir in HSV-seropositive HSCT candidates)
Class: Antiviral. Dose/Timing: Per transplant/ID protocols. Purpose: prevent HSV reactivation during periods of profound immunosuppression. Mechanism: nucleoside analog inhibits viral DNA polymerase. Side effects: renal dosing considerations. Evidence: IDSA recommends HSV prophylaxis in high-risk groups (e.g., allogeneic HSCT). Infectious Diseases Society of America

9) Chlorhexidine (CHX) mouth rinse (short, targeted courses)
Class: Antiseptic oral rinse. Dose/Timing: As dentist/clinician advises (often 0.12%–0.2% 2–3×/day, time-limited). Purpose: reduce mucositis and oral bacterial load to prevent bacteremia. Mechanism: cationic antiseptic disrupts bacterial membranes. Side effects: taste change, tooth staining with long use. Evidence: Clinical statements and reviews support CHX to lower oral microbial load when mechanical cleaning is limited. SpringerLink

10) Granulocyte transfusions (for refractory, life-threatening infections)
Class: Cellular therapy (donor granulocytes). Dose/Timing: Daily infusions for several days until infection control or ANC recovery, under tertiary-center protocols. Purpose: bridge innate immunity during severe infection unresponsive to antibiotics. Mechanism: provides functional neutrophils temporarily. Side effects: alloimmunization, pulmonary reactions. Evidence: Reviews summarize criteria and dosing in severe neutropenia with persistent infections. PMC+1

11) Sargramostim (GM-CSF, LEUKINE®) — selective use
Class: GM-CSF. Dose/Timing: Used in AML post-chemo and other settings; not FDA-approved for SCN. Purpose: sometimes tried when G-CSF response is poor; evidence in JAGN1-SCN shows little benefit, so early HSCT referral is preferred. Mechanism: stimulates myeloid lineage broadly. Side effects: edema, fever; label warnings apply. Evidence: FDA label indications exclude SCN; recent case series in JAGN1-SCN found no sustained neutrophil rise with GM-CSF. FDA Access Data+1

12) Topical antiseptics for skin breaks (e.g., povidone-iodine, alcohol-based)
Class: Antiseptic. Dose/Timing: Immediate wound care. Purpose: prevent cellulitis/bacteremia from minor skin injuries. Mechanism: rapid microbe kill on skin. Side effects: local irritation. Evidence: Standard infection-prevention practice in neutropenia programs. CDC

13) Culture-guided targeted antibiotics
Class: Antibacterial. Dose/Timing: After cultures identify pathogens. Purpose: narrow therapy to reduce resistance and toxicity while clearing infection. Mechanism: pathogen-specific kill. Side effects: drug-specific. Evidence: IDSA principles for neutropenic infections. Infectious Diseases Society of America

14) Antimicrobial lock therapy for infected ports (selected)
Class: Antibacterial/antifungal lock solutions. Dose/Timing: Per ID protocol. Purpose: salvage central lines when feasible. Mechanism: high local antimicrobial concentration disrupts biofilms. Evidence: Incorporated in neutropenic infection care pathways. Infectious Diseases Society of America

15) Pneumocystis prophylaxis when on prolonged immunosuppression
Class: TMP-SMX (or alternatives). Dose/Timing: Specialist-guided. Purpose: prevent PCP in high-risk states (e.g., post-transplant). Mechanism: folate pathway inhibition in Pneumocystis. Evidence: ID practice standards. Infectious Diseases Society of America

16) Antifungal therapy for proven/probable invasive disease
Class: e.g., echinocandins, triazoles. Dose/Timing: Per ID consult. Purpose: treat invasive Candida/Aspergillus. Mechanism: cell wall/membrane inhibition. Evidence: Standard of care within febrile neutropenia pathways. Infectious Diseases Society of America

17) Long-term G-CSF dose optimization
Class: As above. Dose/Timing: Individualized to the lowest dose that prevents infections and maintains safe ANC, balancing potential long-term risks. Purpose: reduce infections with minimal exposure. Mechanism: marrow stimulation calibrated to patient. Evidence: CN registry data emphasize individualized, long-term dosing; AML/MDS transformation risk requires monitoring. PMC

18) Peri-procedural antibiotic prophylaxis (dentistry/ENT as indicated)
Class: Antibacterial. Dose/Timing: Before procedures that breach mucosa in profoundly neutropenic patients. Purpose: prevent bacteremia. Mechanism: covers oral flora at time of tissue injury. Evidence: applied per ID/dental guidelines. SpringerLink

19) RSV/Influenza antivirals when infected (e.g., oseltamivir)
Class: Antiviral. Dose/Timing: Early treatment reduces complications. Purpose: shorten viral shedding/complications. Mechanism: neuraminidase inhibition (influenza). Evidence: antiviral standards within immunocompromised care. CDC

20) Pre-HSCT conditioning and supportive meds (specialist protocols)
Class: multiple (antimicrobials, growth factors, immunosuppression). Purpose: enable curative transplant where G-CSF fails or clonal evolution appears. Evidence: HSCT is the only curative option in SCN; indications include G-CSF resistance or evolution to MDS/AML. ASH Publications+1

---

Dietary molecular supplements

1) Vitamin D
Vitamin D supports bone health and immune function. In SCN6, it can be useful if levels are low, especially given the bone issues reported in SCN. Typical maintenance is 600–1000 IU/day for many children (per clinician; based on serum 25-OH-D). Function/Mechanism: modulates innate/adaptive immunity and bone remodeling. Note: avoid excess; toxicity causes hypercalcemia. Office of Dietary Supplements

2) Vitamin C
Vitamin C helps wound healing and supports immune defenses as an antioxidant. In SCN6, it can support gum and skin integrity with safe food practices. Common dietary intake targets 75–120 mg/day (age-dependent); supplements only if diet is poor. Mechanism: antioxidant; cofactor in collagen formation; supports leukocyte function. Office of Dietary Supplements+1

3) Zinc
Zinc is essential for immune signaling and barrier integrity. Supplement only if deficient, as too much zinc harms copper balance. Doses follow age RDAs (e.g., 2–11 mg/day) unless a clinician prescribes repletion. Mechanism: supports innate/adaptive immunity and epithelial barriers. Office of Dietary Supplements+1

4) Omega-3 fatty acids (dietary focus)
Omega-3s from cooked fish or supplements (clinician-guided dosing) may help overall inflammation balance and tissue repair. Mechanism: cell-membrane mediators that can modulate inflammatory pathways. Note: choose pasteurized/cooked sources; avoid high-mercury fish and raw products. Office of Dietary Supplements

5) β-Glucans (caution; discuss with clinician)
β-glucans can “train” innate immunity in research models, including neutrophil-related pathways. In SCN6, evidence is experimental; safety and benefit are not established for children with severe neutropenia. Mechanism: pattern-recognition receptor signaling that can reprogram innate responses. Use only in trials/with specialist approval. PMC+2PMC+2

6) Multivitamin at RDA levels
For picky eaters or poor intake, a once-daily pediatric multivitamin at RDA levels can prevent gaps. Mechanism: covers baseline micronutrient needs for immune barrier health; avoid megadoses. Office of Dietary Supplements

7) Iron (only if iron-deficient)
Correcting true iron deficiency supports energy and growth; it does not fix neutropenia. Dosing is individualized (often 3–6 mg/kg/day elemental in deficiency). Mechanism: hemoglobin synthesis and cellular metabolism. Caution: give only with labs and supervision. Office of Dietary Supplements

8) Calcium (with vitamin D if needed)
Supports bone mineralization, important if long-term steroids/immobility or low D are present. Mechanism: bone matrix mineral support. Dosing: age-specific RDAs; avoid excess. Office of Dietary Supplements

9) Folate/B12 (only if deficient)
Addressing folate/B12 deficiency can support marrow health broadly, though it does not cure SCN6. Mechanism: DNA synthesis for all dividing cells. Dosing: per labs and clinician. Office of Dietary Supplements

10) Probiotics — generally avoid unless specialist approves
Some cancer centers advise against routine probiotics in severe neutropenia due to rare cases of bacteremia/fungemia; if ever considered, it must be clinician-approved. Mechanism: microbiome modulation. Bottom line: not routinely recommended in SCN6. Blood Cancer UK+1

---

Immunity-booster / regenerative / stem-cell–related drugs

1) Filgrastim (G-CSF) — see above. Dosing: start 6 mcg/kg SC twice daily for congenital neutropenia, titrate. Function/Mechanism: stimulates neutrophil production; cornerstone therapy. FDA Access Data+1

2) Filgrastim biosimilars (Zarxio®, Nivestym®, Releuko®) — interchangeable clinical role with labeled SCN indications (except tbo-filgrastim). Function/Mechanism: same as originator; dosing mirrors filgrastim. FDA Access Data+2FDA Access Data+2

3) Sargramostim (GM-CSF, LEUKINE®) — not SCN-approved; limited or no benefit in JAGN1-SCN; consider early HSCT instead if G-CSF-refractory. Function/Mechanism: broad myeloid stimulation; case reports show poor response in JAGN1. FDA Access Data+1

4) Granulocyte transfusions — temporary donor neutrophils for life-threatening, refractory infections; bridge to recovery/transplant. Dosing often daily for several days. Function/Mechanism: immediate innate immune effect. PMC

5) HSCT (hematopoietic stem-cell transplantation) “drug-assisted” program — the curative pathway when G-CSF fails or clonal evolution occurs. Conditioning medicines, growth factors, and antimicrobials are used per protocol to enable durable donor hematopoiesis. Function/Mechanism: replaces defective marrow with healthy donor stem cells. ASH Publications+1

6) Antiviral/antifungal prophylaxis adjuncts in HSCT — medications such as acyclovir or azoles during transplant periods protect while new marrow engrafts. Function/Mechanism: prevents opportunistic infections until neutrophils recover. Infectious Diseases Society of America

---

Surgeries / procedures

1) Hematopoietic Stem-Cell Transplantation (HSCT)
Procedure: infusion of matched donor stem cells after conditioning. Why: only curative therapy in SCN; indicated for G-CSF resistance, severe infections despite therapy, or evolution toward MDS/AML—especially relevant in JAGN1-SCN poor responders. ASH Publications+1

2) Incision & drainage of abscesses
Procedure: open and drain pus collections not resolving with antibiotics. Why: source control prevents spread in neutropenic patients. Medscape

3) Central venous access device placement
Procedure: port or tunneled catheter insertion. Why: reliable access for IV antibiotics, transfusions, and G-CSF in complex cases. Infectious Diseases Society of America

4) Endoscopic sinus surgery (selected cases)
Procedure: clears obstructed, infected sinuses. Why: reduce chronic bacterial load and recurrent seeding when medical therapy fails. Infectious Diseases Society of America

5) Surgical debridement of deep tissue infections
Procedure: remove necrotic tissue in severe soft-tissue infections. Why: life-saving source control when neutrophils are too low to contain infection. Infectious Diseases Society of America

---

Preventions

1. Master hand hygiene at home and school. CDC

2. Cook meats/eggs fully; wash produce; separate cutting boards. Memorial Sloan Kettering Cancer Center

3. Daily mouth care; use CHX only as directed. SpringerLink

4. Bathe daily; moisturize skin; treat cuts promptly. CDC

5. Avoid close contact with sick people and crowded indoor spaces during high-risk periods. CDC

6. Pet safety: gloves for waste, handwashing after handling. CDC

7. Keep vaccinations updated (inactivated) and vaccinate household contacts. CDC

8. Have a written fever plan and go in immediately for ≥38.0°C. CDC

9. Garden with gloves; avoid compost exposure. CDC

10. Build a hospital emergency pathway for rapid antibiotics. Infectious Diseases Society of America

---

When to see doctors

Seek urgent care now for fever ≥38.0°C, shaking chills, new cough or breathing trouble, rapidly spreading skin redness, mouth ulcers with trouble swallowing, severe sore throat, burning with urination, abdominal or perianal pain, or any sudden decline in well-being. With profound neutropenia, hours matter—early IV antibiotics are life-saving. For routine care, keep regular hematology visits to review growth, dental health, ANC trends, marrow status, and to reassess G-CSF dosing or HSCT timing if responses change. CDC

---

What to eat & what to avoid

• Eat: thoroughly cooked meats, pasteurized dairy, well-washed fruits/vegetables, safely handled eggs (fully cooked), and plenty of fluids; aim for balanced, energy-adequate meals to maintain growth. Avoid: raw/undercooked meats, unpasteurized products, raw eggs, raw sprouts, and cross-contaminated foods. How: wash hands before prep/eating, rinse produce under running water, use separate boards/utensils, chill leftovers quickly, and reheat to safe temperatures. In general, a safe, balanced diet is preferred over an overly restrictive “neutropenic diet.” Memorial Sloan Kettering Cancer Center+1

---

Frequently asked questions

1) Is SCN6 the same as other SCN types?
No. SCN6 is caused by JAGN1 mutations and often responds less to G-CSF than ELANE-related SCN, so some patients move to HSCT earlier. PMC

2) Can SCN6 be cured with medicine alone?
Medicines like filgrastim control infections by raising ANC, but the only curative therapy is HSCT when indicated. ASH Publications

3) Does long-term G-CSF increase leukemia risk?
People with severe chronic neutropenia have a background risk of MDS/AML; long-term registry data show about ~11% developed MDS/AML across CN cohorts—careful monitoring is standard. PMC

4) Which G-CSF products are FDA-approved for SCN?
Filgrastim (Neupogen®) and several biosimilars (Zarxio®, Nivestym®, Releuko®) carry SCN indications and dosing in their labels. Tbo-filgrastim (Granix®) does not have the SCN indication. FDA Access Data+4FDA Access Data+4FDA Access Data+4

5) What starting dose is used?
For congenital neutropenia: 6 mcg/kg twice daily SC is the label-recommended starting point, then titrate. FDA Access Data

6) Are “neutropenic diets” required?
No. Recent evidence favors food-safety practices over strict diet bans; safe prep and cooking matter most. PMC

7) Should we use probiotics?
Generally no in severe neutropenia unless the specialist approves, due to rare bloodstream infections and uncertain benefit. ScienceDirect+1

8) How fast should we act on a fever?
Immediately—contact your team or go to emergency; early antibiotics reduce complications. CDC

9) Can my child attend school?
Yes, with a plan for hand hygiene, quick pick-up when sick, and flexibility during low ANC or infections. CDC

10) Are live vaccines allowed?
Decisions are individualized; many SCN patients receive routine inactivated vaccines, and household vaccination is encouraged. CDC

11) When do we consider HSCT?
If G-CSF resistance or poor response (especially in JAGN1), severe infections despite therapy, or evidence of clonal evolution (MDS/AML). PMC

12) What mouth care works best?
Daily brushing plus saline; short-course chlorhexidine rinses when prescribed can reduce bacterial load. SpringerLink

13) Do supplements replace G-CSF?
No. Supplements may correct deficiencies but do not treat SCN6; G-CSF/HSCT and infection control are the pillars. Office of Dietary Supplements

14) Are granulocyte transfusions permanent fixes?
No—they’re temporary bridges for severe, refractory infections until counts recover or transplant proceeds. PMC

15) What is the long-term outlook?
With expert care, infection prevention, individualized G-CSF, and timely HSCT when needed, many children achieve good outcomes; ongoing monitoring for marrow changes is essential. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.